Abstract:BACKGROUND:Lung cancer has long been the most dangerous malignant tumor among males in both well developed and poorly developed countries. Radiotherapy plays a critical role in the curative management of inoperable non-small cell lung cancer (NSCLC) and is also used as a post-surgical treatment in lung cancer patients. Radioresistance is an important factor that limits the efficacy of radiotherapy for NSCLC patients. Increasing evidence suggests that microRNAs (miRNAs) possess diverse cellular regulatory roles in radiation responses.METHODS:In this study, we used miRNA microarray technology to identify serum miRNAs that were differentially expressed before and after radiotherapy in lung cancer patients. We further examined the biological function of miR-208a on cell viability, apoptotic death and cell cycle distribution in human lung cancer cells and explored the probable mechanism.RESULTS:Nine miRNAs, including miR-29b-3p, miR-200a-3p, and miR-126-3p were significantly down-regulated, whereas miR-208a was the only miRNA that was up-regulated in the serum of the patients after radiation treatment (P < 0.05). The expression of miR-208a could be induced by X-ray irradiation in lung cancer cells. Forced expression of miR-208a promoted cell proliferation and induced radioresistance via targeting p21 with a corresponding activation of the AKT/mTOR pathway in lung cancer cells, whereas down-regulation of miR-208a resulted in the opposite effects. In addition, down-regulation of miR-208a increased the percentage of cells undergoing apoptosis and inhibited the G1 phase arrest in NSCLC cells. Moreover, miR-208a from the serum exosome fraction of lung cancer patients could shuttle to A549 cells in a time-dependent manner, which was likely to contribute to the subsequent biological effects.CONCLUSIONS:The present study provides evidence that miR-208a can affect the proliferation and radiosensitivity of human lung cancer cells by targeting p21 and can be transported by exosomes. Thus, miR-208a may serve as a potential therapeutic target for lung cancer patients.

Mir-339-5p Increases Radiosensitivity of Lung Cancer Cells by Targeting Phosphatases of Regenerating Liver-1 (PRL-1).

Mir-144-5p Enhances The Radiosensitivity Of Non-Small-Cell Lung Cancer Cells Via Targeting Atf2

Mir‑654‑3p Suppresses Cell Viability and Promotes Apoptosis by Targeting RASAL2 in Non‑small‑cell Lung Cancer.

Radiation-induced Mir-208A Increases the Proliferation and Radioresistance by Targeting P21 in Human Lung Cancer Cells.

MiR-99a Enhances the Radiation Sensitivity of Non-Small Cell Lung Cancer by Targeting mTOR

miRNA-218-5p increases cell sensitivity by inhibiting PRKDC activity in radiation-resistant lung carcinoma cells

Extracellular Mir-1246 Promotes Lung Cancer Cell Proliferation and Enhances Radioresistance by Directly Targeting DR5

Mir-300 Regulates Cellular Radiosensitivity Through Targeting P53 and Apaf1 in Human Lung Cancer Cells

Radiosensitizing Effects of Mir‐18a‐5p on Lung Cancer Stem‐like Cells Via Downregulating Both ATM and HIF‐1α

Mir-410 Induces Both Epithelial–mesenchymal Transition and Radioresistance Through Activation of the PI3K/mTOR Pathway in Non-Small Cell Lung Cancer

Role of miR-93-5p and Its Opposing Effect of Ionizing Radiation in Non-Small Cell Lung Cancer

Long Noncoding RNA PTPRG Antisense RNA 1 Reduces Radiosensitivity of Nonsmall Cell Lung Cancer Cells Via Regulating MiR-200c-3p/TCF4

Mir-302A-3p Promotes Radiotherapy Sensitivity of Hepatocellular Carcinoma by Regulating Cell Cycle Via MCL1.

Progress on the Relationship Between Mirna and Lung Cancer in Radiosensitivity

Mechanism Of Mir-512-5p To Promote Radiotherapy Sensitivity Of Lung Cancer By Targeting Sod2

MicroRNA-9 Enhanced Radiosensitivity and Its Mechanism of DNA Methylation in Non-Small Cell Lung Cancer

MicroRNA-499 Serves As a Sensitizer for Lung Cancer Cells to Radiotherapy by Inhibition of CK2α-mediated Phosphorylation of P65

Ectopic Expression of Mir-34A Enhances Radiosensitivity of Non-Small Cell Lung Cancer Cells, Partly by Suppressing the LyGDI Signaling Pathway.

MiR-145 Modulates the Radiosensitivity of Non-Small Cell Lung Cancer Cells by Suppression of TMOD3.

Therapeutic Delivery of Mir-29B Enhances Radiosensitivity in Cervical Cancer.

Target Regulation of Mir-9 to the Expression of NRP1 and Its Role in Radiation Effects